Advocacy intelligence hub — real-time data for patient organizations
Tharimmune Inc — PHASE2
Zydus Therapeutics Inc. — PHASE3
Zydus Therapeutics Inc. — PHASE3
RenJi Hospital
Universitair Ziekenhuis Brussel — NA
Xijing Hospital of Digestive Diseases — PHASE3
Cascade Pharmaceuticals, Inc — PHASE3
Centre Hospitalier Intercommunal Creteil
Hospital Universitario La Paz
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance4
Lynavoy
GlaxoSmithKline
URSO 250
Aptalis Pharma US, Inc.
Ursodiol
AvKARE
OCALIVA
Intercept Pharmaceuticals, Inc.
Livdelzi
(seladelpar)Orphan drugGilead Sciences, Inc.
12.1 Mechanism of Action Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. However, the mechanism by which seladelp...
Iqirvo
(elafibranor)Orphan drugIpsen Bioscience Inc.
Peroxisome Proliferator-activated Receptor Agonist [EPC]
12.1 Mechanism of Action Elafibranor and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of wh...
OCALIVA
(obeticholic acid)Orphan drugIntercept Pharmaceuticals, Inc.
URSO 250
(Ursodiol)Orphan drugAptalis Pharma US, Inc.
Bile Acid [EPC]
12.1 Mechanism of Action Ursodiol, a naturally occurring hydrophilic bile acid, derived from cholesterol, is present as a minor fraction of the total ...
Cynthia Levy, MD
University of Miami
Michael Trauner, Prof, MD
Med. Uni Wien
📍 OXNARD, CA
Michael P Manns, Prof, DC
Med.Hochschule Hannover
📍 GRESHAM, OR
Rong Deng, MD
Cascade Pharmaceuticals, Inc
📍 NEW YORK, NY
Puneeta Tandon
University of Alberta
Lise L Gluud, Professor
Hvidovre University Hospital